Cargando…

Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases

A clinically useful immune biomarker could potentially assist clinicians in their decision making. We stimulated T-cell proliferation to secret interferon gamma (IFN-γ) by phytohemagglutinin, and then measured the production of IFN-γ (mitogen value [M value]). We aimed to determine the relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xing, Liu, Li-Ying, Ji, Xiao-Kun, Xian, Ya-Bin, Yan, Yong-Jun, Xu, Hui-Juan, Sha, Li, Pu, Chun-Li, Zhou, Jun-Yan, Yuan, Chun-Yan, Yang, Mei, Zheng, Song-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709005/
https://www.ncbi.nlm.nih.gov/pubmed/31145331
http://dx.doi.org/10.1097/MD.0000000000015843
_version_ 1783446108522938368
author He, Xing
Liu, Li-Ying
Ji, Xiao-Kun
Xian, Ya-Bin
Yan, Yong-Jun
Xu, Hui-Juan
Sha, Li
Pu, Chun-Li
Zhou, Jun-Yan
Yuan, Chun-Yan
Yang, Mei
Zheng, Song-Guo
author_facet He, Xing
Liu, Li-Ying
Ji, Xiao-Kun
Xian, Ya-Bin
Yan, Yong-Jun
Xu, Hui-Juan
Sha, Li
Pu, Chun-Li
Zhou, Jun-Yan
Yuan, Chun-Yan
Yang, Mei
Zheng, Song-Guo
author_sort He, Xing
collection PubMed
description A clinically useful immune biomarker could potentially assist clinicians in their decision making. We stimulated T-cell proliferation to secret interferon gamma (IFN-γ) by phytohemagglutinin, and then measured the production of IFN-γ (mitogen value [M value]). We aimed to determine the relationship between the M value, clinical severity, and outcomes of diseases. In all, 484 patients admitted to intensive care units were enrolled in this retrospective study. The Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were collected within the first 24 hours. M value, C-reaction protein (CRP), procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and routine blood tests were analyzed and collected during the study. When APACHE II scores were greater than 15 and M values were less than 6, the hospital mortality rose in a straight line. There was an inverse correlation between APACHE II score and M value (r(s) = −0.212, P < .001). There was a positive correlation between M value and lymphocyte numbers (b’ = 0.249, P < .001); however, there was an inverse correlation between M value and WBC (b’ = −0.230, P < .001), and ESR (b’ = −0.100, P = .029). Neurological diseases had the greatest influence on APACHE II scores (b’ = 10.356, P < .001), whereas respiratory diseases had the greatest influence on M value (b’ = 1.933, P < .001). Furthermore, in the respiratory system, severe pneumonia had a greater influence on M value. Taking the APACHE II score as the gold standard, the area under the curve of M was 0.632 (95% confidence interval [CI] 0.575–0.690, P < .001), PCT was 0.647 (95% CI 0.589–0.705, P < .001), CRP was 0.570 (95% CI 0.511–0.629, P = .022), and ESR was 0.553 (95% CI 0.494–0.612, P = .078). Divided by M value = 5, the positive predictive value of the M value is 37.22% (115/309) and negative predictive value is 75.43% (132/175). The results show that the M values, PCT, and CRP were better than ESR to predict the severity of diseases. The number and proportion of lymphocytes also affected the result of the M value. To a certain extent, the M value may be a clinically useful immune biomarker, which may help clinicians objectively evaluate the severity of diseases, especially in the respiratory system.
format Online
Article
Text
id pubmed-6709005
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67090052019-10-01 Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases He, Xing Liu, Li-Ying Ji, Xiao-Kun Xian, Ya-Bin Yan, Yong-Jun Xu, Hui-Juan Sha, Li Pu, Chun-Li Zhou, Jun-Yan Yuan, Chun-Yan Yang, Mei Zheng, Song-Guo Medicine (Baltimore) Research Article A clinically useful immune biomarker could potentially assist clinicians in their decision making. We stimulated T-cell proliferation to secret interferon gamma (IFN-γ) by phytohemagglutinin, and then measured the production of IFN-γ (mitogen value [M value]). We aimed to determine the relationship between the M value, clinical severity, and outcomes of diseases. In all, 484 patients admitted to intensive care units were enrolled in this retrospective study. The Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were collected within the first 24 hours. M value, C-reaction protein (CRP), procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and routine blood tests were analyzed and collected during the study. When APACHE II scores were greater than 15 and M values were less than 6, the hospital mortality rose in a straight line. There was an inverse correlation between APACHE II score and M value (r(s) = −0.212, P < .001). There was a positive correlation between M value and lymphocyte numbers (b’ = 0.249, P < .001); however, there was an inverse correlation between M value and WBC (b’ = −0.230, P < .001), and ESR (b’ = −0.100, P = .029). Neurological diseases had the greatest influence on APACHE II scores (b’ = 10.356, P < .001), whereas respiratory diseases had the greatest influence on M value (b’ = 1.933, P < .001). Furthermore, in the respiratory system, severe pneumonia had a greater influence on M value. Taking the APACHE II score as the gold standard, the area under the curve of M was 0.632 (95% confidence interval [CI] 0.575–0.690, P < .001), PCT was 0.647 (95% CI 0.589–0.705, P < .001), CRP was 0.570 (95% CI 0.511–0.629, P = .022), and ESR was 0.553 (95% CI 0.494–0.612, P = .078). Divided by M value = 5, the positive predictive value of the M value is 37.22% (115/309) and negative predictive value is 75.43% (132/175). The results show that the M values, PCT, and CRP were better than ESR to predict the severity of diseases. The number and proportion of lymphocytes also affected the result of the M value. To a certain extent, the M value may be a clinically useful immune biomarker, which may help clinicians objectively evaluate the severity of diseases, especially in the respiratory system. Wolters Kluwer Health 2019-05-31 /pmc/articles/PMC6709005/ /pubmed/31145331 http://dx.doi.org/10.1097/MD.0000000000015843 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
He, Xing
Liu, Li-Ying
Ji, Xiao-Kun
Xian, Ya-Bin
Yan, Yong-Jun
Xu, Hui-Juan
Sha, Li
Pu, Chun-Li
Zhou, Jun-Yan
Yuan, Chun-Yan
Yang, Mei
Zheng, Song-Guo
Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases
title Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases
title_full Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases
title_fullStr Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases
title_full_unstemmed Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases
title_short Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases
title_sort low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709005/
https://www.ncbi.nlm.nih.gov/pubmed/31145331
http://dx.doi.org/10.1097/MD.0000000000015843
work_keys_str_mv AT hexing lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT liuliying lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT jixiaokun lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT xianyabin lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT yanyongjun lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT xuhuijuan lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT shali lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT puchunli lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT zhoujunyan lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT yuanchunyan lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT yangmei lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases
AT zhengsongguo lowinterferongammareleaseinresponsetophytohemagglutininpredictsthehighseverityofdiseases